Endocyte, Inc. · West Lafayette, IN United States (NASDAQ: ECYT)
| 3000 Kent Ave., Ste. A1-100 | Phone: 765-463-7175 |
| West Lafayette, IN | Fax: 765-463-9271 |
| 47906 | |
| United States | 
Map This Company |
Endocyte, Inc. Rankings
More Companies in These Related Industries: Toxicology LaboratoriesCompany Description
Like "smart bombs," the receptor-targeted therapeutics (or "smart drugs") that Endocyte develops aim to take out bad cells without causing collateral damage. Receptor-targeted therapeutics are a precision alternative to non-targeted cancer drugs that can destroy healthy cells. Founded in 1996, Endocyte uses its drug guidance system to deliver drugs including small molecule cancer drugs and RNA-based therapies directly to cancerous cells, while leaving other cells unaffected. Its lead candidate, EC145 is in clinical trials to treat ovarian cancer. Endocyte went public in early 2011 in a $75 million IPO. It plans to use the proceeds to fund development of EC145 and other candidates in its pipeline.
Endocyte, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: ECYT Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 55 |
Executives
21 executives listed for Endocyte, Inc.'s West Lafayette, IN location.
| Chairman | John Clawson | |
|---|---|---|
| President, CEO, and Director | P. Ron Ellis | |
| CFO | Michael Sherman |